Pacira’s Q3 EXPAREL® sales figure was slightly ahead of our expectations showing 5% growth on Q2 in what is typically a quiet quarter. We continue to expect the growth trajectory to increase in Q4 and for Skyepharma to receive an $8m sales milestone in 2016. We remain bullish on EXPAREL®’s long term growth potential with Pacira working on trials for nerve block, oral surgery and other indications. Discussions are still on-going with partners for EXPAREL® outside of the US. We continue to believe Skyepharma has a highly attractive offering with a diverse product offering and expanding development pipeline.
